Astrazeneca (AZN) Retained Earnings (2009 - 2026)

Astrazeneca (AZN) has reported Retained Earnings for 18 consecutive years, with $9.7 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Retained Earnings rose 187.51% year-over-year to $9.7 billion; the TTM figure through Mar 2026 stood at $9.7 billion (up 187.51% YoY), while the FY2025 annual figure was $11.0 billion, up 247.22% from the prior year.
• Retained Earnings came in at $9.7 billion for Q1 2026 at Astrazeneca, down from $11.0 billion in the prior quarter.
• The five-year high for Retained Earnings was $11.0 billion in Q4 2025, with the low at -$2.5 billion in Q3 2022.
• Average Retained Earnings over 5 years is $2.4 billion, with a median of $1.5 billion recorded in 2023.
• Across the five-year window, Retained Earnings sank 2675.42% in 2022 and soared 1686.79% in 2025, its largest moves.
• Year by year, Retained Earnings stood at -$574.0 million in 2022, then jumped by 361.67% to $1.5 billion in 2023, then soared by 110.39% to $3.2 billion in 2024, then soared by 247.22% to $11.0 billion in 2025, then slipped by 11.85% to $9.7 billion in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered $9.7 billion, $11.0 billion, and $8.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.